Mineralys Therapeutics

Mineralys is a clinical-stage biopharmaceutical company committed to developing best-in-class, novel therapy for the treatment of hypertension.

Mineralys Therapeutics aims to redefine hypertension diagnosis, management and treatment.

Mineralys Therapeutics was founded in 2020 by Catalys Pacific. The company is headquartered in Radnor, Pennsylvania.


Mineralys is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from Mitsubishi Tanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension.


MLS-101 selectivity holds the potential for targeted treatment of blood pressure in hypertension patients with elevated aldosterone production, an underlying cause of hypertension prevalent in at least 25 percent of all hypertensive patients.


Mineralys is backed by RA Capital Management, HBM Healthcare Investments, Samsara BioCapital, Catalys Pacific, Adam Street Partners, Andera Partners, RTW Investments, Rock Springs Capital, SR One Capital Management, and others. The company raised $118M in Series B round on Jun 08, 2022. This brings Mineralys' total funding to $162M to date.



  • Year founded: 2020
  • Funding Info: $162M over 3 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 2-10
  • Business Valuation: NA
  • City/Town: Radnor
  • State: Pennsylvania
  • Country: United States
Related businesses